Deutsche Bank
MPLT

Deutsche Bank’s MapLight Therapeutics MPLT Stock Holding History

Deutsche Bank’s Portfolio MPLT Stock Details MPLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$370K Sell
10,326
-3,353
-25% -$96.4K ﹤0.01% 2934
2026
Q1 		$278K Buy
13,679
+1,751
+15% +$31.3K ﹤0.01% 2859
2025
Q4 		$210K Buy
+11,928
New +$200K ﹤0.01% 2991

Other funds holding MPLT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $131M AUM 86.64% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Deutsche Bank's MPLT Position: Q2 2026 in Review

Deutsche Bank reduced its MapLight Therapeutics (MPLT) stake by 25% in Q2 2026, selling an estimated $96.4K and leaving 10,326 shares worth $370K. The position accounts for ﹤0.01% of the portfolio, ranked #2934.

Deutsche Bank first reported a position in MPLT in Q4 2025 and has held it in 3 quarters since. 105 funds tracked by Wall St. Rank hold MPLT as of Q2 2026.

  • Deutsche Bank held 10,326 shares of MapLight Therapeutics worth $370K as of Q2 2026.
  • Deutsche Bank sold 3,353 MapLight Therapeutics shares in Q2 2026, an estimated $96.4K.
  • MapLight Therapeutics made up ﹤0.01% of Deutsche Bank's portfolio in Q2 2026, its #2934 holding.
  • Deutsche Bank first reported a position in MapLight Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 105 funds tracked by Wall St. Rank held MapLight Therapeutics as of Q2 2026.

Based on Deutsche Bank's 13F filing for Q2 2026, filed 7 Aug 2026.